



Journal of Advanced Pharmaceutical Technology & Research

An Official Publication of Society of Pharmaceutical Education & Research

Volume 13 / Issue 4 / October-December 2022

www.japtr.org





Table of Contents



October-December 2022

Volume 13 | Issue 4

Page Nos. 243-328

Online since Monday, October 10, 2022

Accessed 12,455 times.

PDF access policy

Journal allows immediate open access to content in HTML + PDF

EPub access policy

allows EPub access only to users from **INDIA**, developing countries and paid subscribers.

[View issue as eBook](#)

[Issue statistics](#)

[RSS](#)

[Show all abstracts](#)

[Show selected abstracts](#)

[Export selected to](#) ▼

[Add to my list](#)

Feedback

[Subscribe](#)

[Next Issue](#)

[Previous Issue](#)

[Most popular articles](#)

[Join as Reviewer](#)

[Email alerts](#)

[Recommend this journal to your library](#)


REVIEW ARTICLE

Cancer and disease diagnosis - Biosensor as potential diagnostic tool for biomarker p. 243 detection

Gul-e-Saba Chaudhry, Abdah Md Akim, Naila Safdar, Azra Yasmin, Shaheen begum, Yeong Yik Sung, Tengku Sifzizul Tengku Muhammad

DOI:10.4103/japtr.japtr_106_22

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}




ORIGINAL ARTICLES

Clinical practice guidelines for radiographic assessment in management of oral cancer p. 248

LM Abhinaya, Arvind Muthukrishnan

DOI:10.4103/japtr.japtr_129_22

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}




Formulation and characterization of orodispersible tablet of glimepiride p. 252

Ahmad AB Yosef Kinani, Hassanien Sagban Taghi

DOI:10.4103/japtr.japtr_375_22

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}




In vivo study of bovine hydroxyapatite-gelatin-hydroxypropyl methylcellulose with alendronate as injectable bone substitute composite in osteoporotic animal model p. 261

Aniek Setiya Budiatiin, Maria Apriliani Gani, Bulan Rhea Kaulika Hadinar Putri, Samirah Samirah, Dyah Hikmawati,

Alfian Pramudita Putra, Nily Su'aidah, Junaidi Khotib

DOI:10.4103/japtr.japtr_266_22

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}




A cross-sectional study on assessing depression among hemodialysis patients p. 266

Aeshah Hamed Albuhayri, Areej Rabea Alshaman, May Naif Alanazi, Ruwaa Muteb Aljuaid, Reem Ibrahim

Mobark Albalawi, Shouq Salem Albalawi, Mohammed Omar Alsharif, Nouf M Alharthi, Kousalya Prabarah

DOI:10.4103/japtr.japtr_322_22

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}




The effectiveness of forest honey toward symptoms of atrophy patients: Study of ear nose and throat-head neck and dermatology venereology p. 271

Asrawati Sofyan, Christin R Nayoan, Andi Nur Asrinawaty

DOI:10.4103/japtr.japtr_359_22

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}





Anabasis articulata exerts an anti-arthritic effect on adjuvant-induced arthritis in rats p. 276

Zaid Hamzah Abdulhusain, Makarim A Mahdi, Waleed K Abdulsahib, Layth S Jasim

DOI:10.4103/japtr.japtr_440_22

[\[ABSTRACT\]](#) [\[HTML Full text\]](#) [\[PDF\]](#) [\[Mobile Full text\]](#) [\[EPub\]](#) [\[Sword Plugin for Repository\]](#)^{Beta}






Cytotoxicity and phytochemical profiles of *Phyllanthus emblica* stem barks with *in silico* drug-likeness: Focusing on antidiabetic potentials p. 281

Quranayati Quranayati, Muhammad Iqhrammullah, Nurdin Saidi, Nurliana Nurliana, Rinaldi Idroes, Rosnani Nasution

DOI:10.4103/japtr.japtr_319_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}



Problems of purchasing pharmacy products through online orders p. 286

Mariia Sergeevna Soboleva, Ekaterina Efimovna Loskutova, Irina Vladimirovna Kosova

DOI:10.4103/japtr.japtr_454_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}




Evaluation of adverse drug reaction in patients warfarin therapy p. 291

Norisca Aliza Putriana, Taofik Rusdiana, Tina Rostinawati, Mohammad Rizki Akbar, Dika Pramita Destiani

DOI:10.4103/japtr.japtr_439_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}




Ethanol extract of *Lannea coromandelica* stem bark: Histopathology and infiltration of inflammatory cells in the rat's gastric p. 296

Achmad Ramadhan, Hastuti Herman, Sutrisnawati Sutrisnawati

DOI:10.4103/japtr.japtr_475_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}




Cytotoxicity and antiproliferative activity of ethanol and ethyl acetate fractions from polymeric nanoparticles of green tea leaves (*Camellia sinensis*) in breast cancer cell line MDA-MB-132 p. 301

Mimin Kusmiyati, Agus Rusdin, Elvi Trinovani, M Iqbal Prawira-Atmaja, Dicki Bakhtiar Purkon, Gurid Pramintarto Eko Mulyo

DOI:10.4103/japtr.japtr_422_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}




Preparation and evaluation of oral soft chewable jelly containing flurbiprofen p. 306

Lubna Abdalkarim Sabri, Abeer H Khasraghi, Hala Talal Sulaiman

DOI:10.4103/japtr.japtr_465_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}



Phytochemical screening, quantitative analysis of cyanidin-3-O-glucoside content, and anticancer activity of novel rice bran (Tubtim Chumphae rice) p. 312

Rittipun Rungruang, Napassom Peasura, Nattapon Kaisangsri

DOI:10.4103/japtr.japtr_458_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}




Evaluation of proximate composition and biological activities of sompoi (*Acacia concinna*) leaves in Thailand p. 317

Aunyachulee Ganogpichayagrai, Chutinana Suksaard

DOI:10.4103/japtr.japtr_443_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}



Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines p. 322

Riska Prasetyawati, Syahrul Hidayat, Adel Zamri, Muchtaridi Muchtaridi

DOI:10.4103/japtr.japtr_435_22

[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]^{Beta}



[Home](#) | [About JAPTR](#) | [Editorial board](#) | [Search](#) | [Ahead of print](#) | [Current issue](#) | [Archives](#) | [Submit article](#) | [Instructions](#) | [Subscribe](#)

Editorial Board

Editor-in-Chief

Dr. Upendra Nagaich

M.Pharm., Ph.D., FSPER

Professor & Research Coordinator,

Amity Institute of Pharmacy, Amity University,

Noida (U.P.) India

&

National Secretary,

[Society of Pharmaceutical Education & Research \(SPER\), India](#)

R4

Executive Editors

Dr. Paul Wan Sia Heng

Department of Pharmacy,

National University of Singapore,

Singapore

Dr. Jaya Pandey

School of Studies in Pharmaceutical Sciences,

Jiwaji University,

Gwalior (M.P.) India

Associate Editor

Dr. Vandana Chaudhary

School of Pharmacy,

Pharmacy Australia Centre of Excellence,

The University of Queensland,

Brisbane, Australia

Consultant Editor

Prof. (Dr.) Laszlo Endrenyi

Professor Emeritus

Department of Pharmacology & Toxicology

University of Toronto, Toronto, Canada

Section Editors (Alphabetical Order)

Dr. Ikoni Ogaji

Dept. of Pharmaceutics & Pharmaceutical Technology,

Faculty of Pharmaceutical Sciences,

University of Jos, Nigeria

Dr. Ke Li

J. David Gladstone Institutes,

San Francisco, California, USA

Editorial Board Members (In Alphabetical Order)**Prof. (Dr.) A. N. Kalia**

Vice-President, Society of Pharmacognosy,
Professor & Head
I.S.F. College of Pharmacy,
Moga (Punjab), India

Dr. Abdul Wahab

Department of Pharmacy
Kohat University of Science & Technology
Kohat, KPK, Pakistan

Prof. (Dr.) Arun Dharmarajan

Professor
School of Biomedical Sciences,
Faculty of Health Sciences,
Curtin University,
Perth, Australia

Prof. (Dr.) Ashoke Kumar Ghosh

Vice-Chancellor
IFTM University,
Moradabad (Uttar Pradesh), India

Prof. (Dr.) B. Mishra

Professor & Head
Department of Pharmaceutics,
Indian Institute of Technology,
Banaras Hindu University,
Varanasi (Uttar Pradesh), India

Prof. B. G. Shivananda

Secretary, APTI
Bangalore (Karnataka), India

Prof. (Dr.) Bharat B. Aggarwal

Professor of Cancer Medicine &
Chief, Cytokine Research Laboratory
The University of Texas
Texas, USA

Dr. Bhaswat Sundar Chakraborty

Senior VP & Chairman, R&D Core Committee
Cadila Pharmaceuticals Ltd.
Ahmedabad (Gujarat), India

Prof. (Dr.) C. K. Kokate

National Advisor, Society of Pharmacognosy,
Vice-Chancellor
KLE University,
Belgaum (Karnataka), India

Prof. (Dr.) Cedric Pearce

Adjunct Professor
University of North Carolina
CEO, Mycosynthetix Inc.
North Carolina, USA
[Associate Editor, Journal of Natural Products]

Prof. (Dr.) Ciddi Veeresham

Professor
University College of Pharmaceutical Sciences,

Kakatiya University,
Warangal (Andhra Pradesh), India

Dr. Dâmaris Silveira
Universidade de Brasília
Brasília, Brazil

Prof. (Dr.) Dilipkumar Pal
Professor
Dept. of Pharmaceutical Sciences,
Guru Ghasidas Vishwavidyalaya,
Bilaspur (Chhattisgarh), India

Prof. (Dr.) Divakar Goli
Associate Secretary, IPA
Secretary, Education Division, IPA
Professor & Principal
Acharya & B.M. Reddy College of Pharmacy,
Bangalore (Karnataka), India

Prof. (Dr.) G. K. Dash
Professor
Universiti Kuala Lumpur
Perak Darul Ridzuan, Malaysia

Prof. (Dr.) H. S. Buttar
Adjunct Professor,
School of Medicine,
University of Ottawa,
Ottawa, Canada

Kaushik Desai
Gen. Secretary, IPA
Immediate Vice President, IPA
Mumbai (Maharashtra), India

Prof. (Dr.) Mainul Haque
Professor
Universiti Sultan Zainal Abidin
Kuala Terengganu, Terengganu, Malaysia

Dr. Muhammad Akhlaq
University of Auckland
Auckland, New Zealand

Prof. (Dr.) N. Udupa
Professor & Research Director [Health Sciences]
Manipal University,
Manipal (Karnataka), India

Prof. (Dr.) Pomsak Sriamomsak
Professor,
Department of Pharmaceutical Technology &
Pharmaceutical Biopolymer Group (PBiG),
Faculty of Pharmacy, Silpakorn University,
Nakhon Pathom, Thailand

Dr. Rakesh Kumar Sharma
Scientist 'F'
Director,
Defence Food Research Laboratory (DFRL),
Mysuru (Karnataka), India

Prof. (Dr.) Roop K. Khar

Former Professor
Department of Pharmaceutics,
Jamia Hamdard (Hamdard University)
New Delhi, India

Prof. (Dr.) Roopa Karki
Professor & Head
Department of Pharmaceutics,
Acharya & BM Reddy College of Pharmacy,
Bangalore (Karnataka), India

Prof. (Dr.) S. D. Tonpay
Former Professor & Head
Govt. Gajra Raja Medical College,
Gwalior (Madhya Pradesh), India

Prof. (Dr.) S. H. Ansari
Professor & Head,
Department of Pharmacognosy & Phytochemistry,
Jamia Hamdard (Hamdard University)
New Delhi, India

Prof. (Dr.) S. H. Mishra
Professor Emeritus
Faculty of Pharmacy,
The M. S. University of Baroda,
Vadodara (Gujarat), India

Prof. (Dr.) Satish Sardana
Immediate Past President, APTI (Haryana)
Director,
Amity Institute of Pharmacy,
Amity University,
Manesar (Haryana), India

Prof. (Dr.) T. V. Narayana
President, IPA
Director
Vikas Institute of Pharmaceutical Sciences
Rajahmundry (Andhra Pradesh), India


Prof. (Dr.) V. K. Dixit
President, Society of Pharmacognosy,
Former Professor
Department of Pharmaceutical Sciences,
Dr. H. S. Gour University,
Sagar (M.P.), India

Prof. (Dr.) Y. K. Agrawal
Director
Institute of Research & Development,
Gujarat Forensic Sciences University,
Gandhinagar (Gujarat), India

[Sitemap](#) | [What's New](#) [Feedback](#) | [Contact Us](#)

© Journal of Advanced Pharmaceutical Technology & Research

Editorial Board



In vivo study of bovine hydroxyapatite-gelatin-hydroxypropyl methylcellulose with alendronate as injectable bone substitute composite in osteoporotic animal model

Aniek Setiya Budiati,
 Maria Apriliani Gani,
 Bulan Rhea Kaulika Hadinar Putri,
 Samirah Samirah,
 Dyah Hikmawati,
 Alfian Pramudita Putra,
 Nily Su'aidah, Junaidi Khotib

Department of Pharmacy Practice,
 Faculty of Pharmacy, Airlangga
 University, Surabaya, Indonesia

J. Adv. Pharm. Technol. Res.

ABSTRACT

The injectable bone substitute (IBS) is a self-setting local drug delivery system that adjusts the shape of the bone gap in the fracture. This study aimed to examine the effectiveness of IBS composites of bovine hydroxyapatite (BHA) and alendronate (Ale) in accelerating bone growth in osteoporotic rats. IBS was made by mixing BHA with gelatin 5%, hydroxypropyl methylcellulose (HPMC) 2%, and Ale 10%. The physical properties of IBS were viscosity, injectability, and density tests. Twenty-four female Wistar rats were divided into four groups. After 8 weeks, 2 mm gap was made in the right femur of all rats and filled with IBS. The healing process was observed after 6 weeks with X-ray imaging and H and E staining. The obtained results showed viscosity, injectability, and density value of IBS from 30.4 to 39.4 dPa.s, 98.22%–98.64%, and 0.6325–0.8409 g/cm³, respectively. X-ray imaging and histology results proved the condition of osteoporosis in rats with ovariectomy. The addition of BHA-Gel-HPMC-Ale significantly affected the number of osteoblasts, osteocytes, and osteoclasts ($P < 0.05$). After 45 days of observation, the addition of BHA-Gel-HPMC-Ale showed the highest mean number of osteoblasts, osteocytes, and osteoclasts, which were 25.00 ± 3.00 , 64.33 ± 11.15 , and 5.67 ± 0.58 compared to BHA-Gel-HPMC and positive control groups. The BHA-Gel-HPMC-Ale IBS has the potential to reverse osteoporosis. Nevertheless, the underlying potential of these biomaterials to reverse osteoporosis needs further research.

Key words: Alendronate, bovine hydroxyapatite, fracture, injectable bone substitute, osteoporosis

Address for correspondence:

Dr. Aniek Setiya Budiati,
 Perum Griya Airlangga, D 17 Wonorejo Selatan, Rungkut,
 Surabaya, Indonesia.
 E-mail: anieksb@yahoo.co.id

Submitted: 28-Apr-2022

Revised: 13-Jun-2022

Accepted: 16-Jun-2022

Published: 10-Oct-2022

Access this article online

Quick Response Code:



Website:

www.japtr.org

DOI:

10.4103/japtr.japtr_266_22

INTRODUCTION

Osteoporosis is a systemic disease characterized by a gradual decrease in bone density (T-score ≤ -2.5) and the damage to the bone tissue microarchitecture, resulting in an increase in bone fragility and the risk of fractures or large fractures gap formation. Osteoporosis occurs due to an imbalance

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Budiati AS, Gani MA, Putri BR, Samirah S, Hikmawati D, Putra AP, et al. In vivo study of bovine hydroxyapatite-gelatin-hydroxypropyl methylcellulose with alendronate as injectable bone substitute composite in osteoporotic animal model. *J Adv Pharm Technol Res* 2022;13:261-5.

between osteoclast and osteoblast activity, making the resorption process higher than the bone formation process. Data from the International Osteoporosis Foundation in 2015 stated that 1 in 3 women and 1 in 5 men experienced an osteoporosis-related fracture at 50 years worldwide.^[1-3]

The injectable bone substitute (IBS) is a local drug delivery system that adapts the shape of the bone gap to fracture, a minimally invasive treatment method, and an alternative route for delivery of high drug concentration.^[4,5] The injectable system was aimed at the bone gap due to osteoporotic cases, which contained inorganic and organic components that resemble the structure of the bone matrix.^[6,7]

Alendronate (Ale) is a bisphosphonate drug used to prevent and treat osteoporosis. There are two mechanisms of Ale acting as an inhibitor of the farnesyl pyrophosphate synthase enzyme. This enzyme increases osteoclast activity and binds to calcium from bone hydroxyapatite. As a result, osteoclast activity for bone resorption decreased.^[8] In oral use, Ale has low bioavailability (1%–5%). In addition, it also causes side effects, such as gastrointestinal disorders and osteonecrosis of the facial jaw, if consumed for a long time.^[3,7,9]

Delivery of Ale in the bone tissue can be supported by bovine hydroxyapatite (BHA). BHA is hydroxyapatite from bovine bone, which has chemical and physical properties similar to human bone. Besides, gelatin (Gel) is a polymer that resembles an organic component of bone tissue. BHA and Gel help accelerate bone growth in damaged bone tissue.^[7] In addition, hydroxypropyl methylcellulose (HPMC) is an inert, viscoelastic polymer used for controlled delivery.^[7,10] BHA-Gel-HPMC composite could be an excellent delivery system for Ale in the bone tissue.

This study aimed to examine the BHA-Gel-HPMC IBS composite in osteoporotic bone tissue engineering as a filler to strengthen bone mechanical properties and Ale delivery system.

MATERIALS AND METHODS

Synthesis dan characterization of injectable bone substitute

The IBS was synthesized by dissolving Gel powder 5% into distilled water at 40°C for 1 h. BHA was added to the Gel solution with a ratio of 45:55 and stirred for 1 h. Then, Ale was mixed with the BHA-Gel solution with the composition of 10% from the mass of BHA in each sample and stirred until homogeneous. HPMC 2% (w/v) was dissolved with distilled water at 90°C until the temperature decreased to 40°C. The HPMC solution was poured into the BHA-Gel-Ale mixture at 40°C and stirred for 6 h. The physical characterization was carried out by using a viscometer.

The injectability test was carried out by inserting the suspension into a 10 ml syringe with an inside diameter of 2 mm and a 1.2 mm inner diameter syringe needle within 2 min with variations of temperature: 15°C, 25°C, 35°C, and 45°C. The setting time test was carried out by injecting IBS into the HA substrate, then observing the setting process that occurred. The injected suspension in the HA substrate was conducted at 25°C close to room temperature and 35°C close to body temperature.

In vivo test

200–250 g 3 months old Wistar rat (*Rattus norvegicus*) were used in the experiments. This research has been approved by the Ethical Committee in the Faculty of Veterinary Medicine in Airlangga University, Indonesia, with reference number 2.KE.075.05.2018. After an adaptation period of 1 week, 24 rats were randomly divided into four groups: control negative group (healthy group, P1), control positive group (P2), BHA-Gel-HPMC Group (P3), and BHA-Gel-HPMC-Ale (P4). The positive control group underwent ovariectomy without bone filler. After 8 weeks, the pre-surgery treatment was performed by anesthetizing the rat with ketamine (25 mg/kg) and xylazine (8 mg/kg) I. M in the left leg.^[11] The incision in the abdomen was performed through linea alba. The ovarium was removed, and the open abdomen was sutured. The osteoporosis took place after 8 weeks.

After 8 weeks of ovariectomy, the treatment of bone filler was performed by anesthetizing the rat.^[11] The fracture was made on the rat's femur in the lengthwise direction and incision was performed in the femur until the bone. The drilling on the bone was performed to make a hole with a diameter of 2 mm. The IBS was then injected into the hole, and the opened skin was sutured.

Histopathology

After 6 weeks of bone filler injection, the rats were terminated by using ether anesthesia. The femur bone was stored in the 10% BNF. Bone decalcification was performed in 10% Ethylenediaminetetraacetic acid solution. The bone cell observation was observed with H and E (HE) staining, and the bone gap was observed radiologically. The bone cell observation included osteoblast, osteoclast, and osteocytes. They were observed under a light microscope with a magnification of 400 times.

Statistical analysis

Results obtained are showed as mean \pm standard deviation. Independent sample *t*-test was used to evaluate the difference between control positive and negative group. One way analysis of variance was to analyze osteoblast, osteoclast, and osteocytes scoring. *P* < 0.05 was stated statistically significant differences.

RESULTS AND DISCUSSION

Injectable bone substitute characteristics

The viscosity test was carried out to determine the thickness of the suspension synthesized as a function of temperature and ensure the viscosity of the HPMC suspension viscosity standard value of 2% (w/v) as a bone substitute application, which is 40 dPa.s.^[7] The IBS viscosity test results obtained viscosity between 30.4 and 39.4 dPa.s. The viscosity of IBS and the temperature of IBS greatly affected by injectability.^[5] The percentage of injectability is between 98.22% and 98.64% at 25° C–35°C was able to set and increased the substrate density from 0.6325 g/cm³ to 0.8409 g/cm³ according to normal bone density. The physical properties of IBS allowed IBS BHA-Gel-HPMC to be applied to treat osteoporosis.

Anatomical pathology test results

The results of X-ray imaging on the rat's femur after 6 weeks in the P1, P2, P3, and P4 groups are shown in Figure 1. The gap size was calculated using ImageJ v1.44p software, as shown in Table 1. The results showed that osteoporosis had occurred in positive control. In addition, the results of the analysis of P2 showed a significant difference ($P < 0.05$) in the bone gap size compared to P1 [Table 1]. Ovariectomy has been shown to cause osteoporosis. The ovariectomy triggers excessive osteoclast activity, which causes an imbalance of bone remodeling, promoting bone resorption and decreasing bone regeneration.^[12] Osteoporosis-related estrogen deficiency suppressed the osteocyte life sustainability and disrupted the physiological response of osteoblasts for mechanical stimulation, damage detection, and bone repair.^[13]

Moreover, as shown in Table 2, the positive control groups P3 and P4 were not significantly different ($P > 0.05$) in compare to P2. Ale concentration 10% in BHA-Gel-HPMC used was less than optimal for the balance of bone formation, and the lack of observation time affects the number of cell growth. Ale would suppress osteoclast activity excessively which made bone remodeling suppressed and decrease the bone formation and caused a delay in bone grafting.^[14,15] The observation's times played a vital role in assessing the

effectiveness of Ale. Based on the remodeling process, bone takes 3–4 months or years to complete the fully regenerated bone structure.^[16-18]

Observation of bone cell growth was also carried out for the femoral gap through a histopathological test with HE staining. The cells observed included osteoblast, osteocyte, and osteoclast with a magnification of $\times 400$. The results are shown in Figure 2, and the mean numbers of osteoblasts, osteocytes, and osteoclasts between treatment groups are shown in Table 3. HE staining results showed the number of osteoblasts and osteoclasts in P2 significantly different ($P < 0.05$) compared to P1. The average number of osteoblasts in P2 is 14.33 ± 2.52 , while the average number of osteoblasts in P1 is 9.00 ± 1.73 and the average number of osteoclasts in P2 is 10.00 ± 2.00 . The number of osteocytes in the P2 was not significantly different ($P > 0.05$) compared to P1. Based on the result of the independent *t*-test in P2, the addition of BHA-Gel-HPMC-Ale (P4) significantly affected the number of osteoblasts, osteocytes, and osteoclasts ($P < 0.05$). After 45 days of observation, the

Table 1: Injectable bone substitute physical properties

Parameter	Value
Viscosity	30.4-39.4 dPa.s
Injectability	98.22-98.64%
Density	0.6325 g/cm ³ to 0.8409 g/cm ³

Table 2: Bone gap size between positive control, bovine hydroxyapatite-Gel-hydroxypropyl ethylcellulose, and bovine hydroxyapatite-Gel-hydroxypropyl ethylcellulose-Ale (mean \pm standard deviation)

Group	Bone gap size (mm)
Negative control	1.046 \pm 0.013
Positive control	1.784 \pm 0.027 ^a
BHA-Gel-HPMC	1.750 \pm 0.017
BHA-Gel-HPMC-Ale	1.752 \pm 0.022 ^b

^a $P < 0.05$ versus negative control, ^b $P > 0.05$ versus negative control and positive control. HPMC: Hydroxypropyl ethylcellulose, BHA: Bovine hydroxyapatite




Figure 1: Radiological X-ray image representation of bone gap size: Negative control (P1), positive control (P2), BHA-Gel-HPMC (P3), BHA-Gel-HPMC-Alendronate (P4). HPMC: Hydroxypropyl ethylcellulose, BHA: Bovine hydroxyapatite




Figure 2: H and E staining results; osteoblasts (red arrow), osteocytes (black arrow), osteoclasts (triangle). (a) Negative control; (b) Positive control; (c) BHA-Gel-HPMC (d) BHA-Gel-HPMC-Alendronate. HPMC: Hydroxypropyl ethylcellulose, BHA: Bovine hydroxyapatite

addition of BHA-Gel-HPMC-Ale (P4) showed the highest average number of osteoblasts, osteocytes, and osteoclasts 25.00 ± 3.00 , 64.33 ± 11.15 , and 5.67 ± 0.58 , respectively, in compared to P3 and P1.

The result showed that the number of osteoblasts, osteocytes, and osteoclasts in group BHA-Gel-HPMC with Ale (P4) showed a significant difference ($P < 0.05$) in compared to P2 and P3. This study showed the same results as the research conducted by Toker *et al.* After 8 weeks, they evaluated the local effect of Ale and calcium phosphate combination on calvarial bone defects in rats.^[19] The results showed no significant difference between the two groups (P3 and P4) on the number of osteoblasts or osteoclasts. This result showed that the bone formation process was still happening. When injected into the bone gap, Ale binds to BHA form a very strong bond, while Ale distributed in the Gel-HPMC released and binds to the calcium hydroxyapatite of the bone around the gap. It caused the bone around the gap became solid and hard. Gel-HPMC interacted with osteoblasts to form osteoid. Osteoid turn into osteocytes with bone calcium and calcium from BHA.^[7,20,21]

CONCLUSIONS

The results of physical characteristics test showed that BHA-Gel-HPMC-Ale has potential as treatment for osteoporosis. Moreover, X-ray imaging and histopathological tests proved that ovariectomy in Wistar rat resulted in an osteoporosis model. The IBS combination did not accelerate narrowing the bone gap based on the results of X-ray imaging. The results of HE staining showed that the injectable BHA-Gel-HPMC increased the number of osteoblasts, osteocytes, and osteoclasts in ovariectomy rat models. The addition of Ale did not increase the number of osteoblasts, osteocytes, and osteoclasts within 6 weeks of observation in compared to BHA-Gel-HPMC. It is recommend to observe more than 6 weeks to prove the addition of Ale in accelerating of bone growth.

Table 3: The number of osteoblasts, osteocytes, and osteoclasts between positive control, bovine hydroxyapatite-Gel-hydroxypropyl ethylcellulose, and bovine hydroxyapatite-Gel-hydroxypropyl ethylcellulose-Ale (mean±standard deviation)

Group	Osteoblast	Osteocyte	Osteoclast
Negative control	9.00±1.73	15.33±4.51	0.00±0.00
Positive control	14.33±2.52	16.67±5.03	10.00±2.00
BHA-Gel-HPMC	20.33±4.51	55.67±6.03 ^b	2.67±0.58 ^c
BHA-Gel-HPMC-Ale	25.00±3.00 ^a	64.33±11.15 ^{bb}	5.67±0.58 ^{cc}

^a $P < 0.05$ versus positive control and negative control, ^b $P < 0.05$ versus positive control and negative control, ^{bb} $P < 0.05$ versus positive control and negative control, ^c $P < 0.05$ versus positive control and negative control, ^{cc} $P < 0.05$ versus positive control and negative control. HPMC: Hydroxypropyl ethylcellulose, BHA: Bovine hydroxyapatite

Acknowledgment

The authors would like to thank Research under the Ministry of Research, Technology and Higher Education, Republic of Indonesia (RISTEKDIKTI RI).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Oei L, Koromani F, Rivadeneira F, Zillikens MC, Oei EH. Quantitative imaging methods in osteoporosis. *Quant Imaging Med Surg* 2016;6:680-98.
- Khotib J, Gani MA, Budiatin AS, Lestari ML, Rahadiansyah E, Ardianto C. Signaling pathway and transcriptional regulation in osteoblasts during bone healing: Direct involvement of hydroxyapatite as a biomaterial. *Pharmaceuticals (Basel)* 2021;14:615.
- Gani MA, Nurhan AD, Budiatin AS, Siswodihardjo S, Khotib J. Predicting the molecular mechanism of glucosamine in accelerating bone defect repair by stimulating osteogenic proteins. *J Basic Clin Physiol Pharmacol* 2021;32:373-7.
- Capra P, Dorati R, Colonna C, Bruni G, Pavanetto F, Genta I, *et al.* A preliminary study on the morphological and release properties of hydroxyapatite-alendronate composite materials. *J Microencapsul* 2011;28:395-405.
- Hikmawati D, Maulida HN, Putra AP, Budiatin AS, Syahrom A. Synthesis and characterization of nanohydroxyapatite-gelatin composite with streptomycin as antituberculosis injectable bone substitute. *Int J Biomater* 2019;2019:7179243.
- Tran RT, Gyawali D, Nair P, Yang J. Biodegradable Injectable Systems for Bone Tissue Engineering, a Handbook of Applied Biopolymer Technology: Synthesis, Degradation and Applications. Royal Society of Chemistry No. 12; 2013. p. 419-51.
- Budiatin AS, Gani MA, Ardianto C, Samirah, Pattah SY, Mubarakah F, *et al.* The impact of glutaraldehyde on the characteristics of bovine hydroxyapatite-gelatin based bone scaffold as gentamicin delivery system. *J Basic Clin Physiol Pharmacol* 2021;32:687-91.
- Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. *Mayo Clin Proc* 2008;83:1032-45.
- Bourges X, Weiss P, Daculsi G, Legeay G. Synthesis and general

- properties of silated-hydroxypropyl methylcellulose in prospect of biomedical use. *Adv Colloid Interface Sci* 2002;99:215-28.
10. Putra AP, Faradisa I, Hikmawati D, Siswanto. The Effect of Hydroxyapatite-Gelatin Composite with Alendronate as Injectable Bone Substitute on Various Hydroxyapatite-Based Substrate 2019 International Biomedical Instrumentation and Technology Conference. IBITeC; 2019. p. 41-5.
 11. Kilic N, Henke J, Pragst I, Erhardt W. Comparison of three different medetomidine/ketamine combinations in NMRI mice. *Vet Anaesth Analg* 2001;28:211-2.
 12. Syafikriatillah AR, Darwis D, Abbas B, Maheshwari H, Erwin E, Noviana D. White Blood Profile of Sprague Dawley Rat Post-Implantation of DFDBX Bone Marking and Nata De Coco Membrane in Calvary Bone Defect. *Prosiding KIVNAS ke-14, ICEBSD City, Tangerang 22-25 September, 2016*. p. 10-1.
 13. Erpek S, Kılıç N, Kozacı LD, Dikicioğlu E. Effects of flunixin meglumine, diclofenac sodium and metamizole sodium on experimental wound healing in rats. *Rev Med Vet* 2006;157:185-92.
 14. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. *Trends Mol Med* 2006;12:17-25.
 15. Rodriguez EK, Zurakowski D, Herder L, Hall A, Walley KC, Weaver MJ, *et al.* Mechanical construct characteristics predisposing to non-union after locked lateral plating of distal femur fractures. *J Orthop Trauma* 2016;30:403-8.
 16. Sloan AV, Martin JR, Li S, Li J. Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. *Bone* 2010;47:235-40.
 17. Park SB, Lee YJ, Chung CK. Bone mineral density changes after ovariectomy in rats as an osteopenic model: Stepwise description of double dorso-lateral approach. *J Korean Neurosurg Soc* 2010;48:309-12.
 18. O'connel MB, Seaton TL. Osteoporosis and osteomalacia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. *Pharmacotherapy: A Pathophysiologic Approach*. 6th ed., Ch. 88. New York: McGraw-Hill Companies, Inc.; 2005. p. 1645-66.
 19. Toker H, Ozdemir H, Ozer H, Eren K. Alendronate enhances osseous healing in a rat calvarial defect model. *Arch Oral Biol* 2012;57:1545-50.
 20. Barrere F, van BC, de GK, Layrolle P. Nucleation of biomimetic Ca-P coatings on ti6A14V from a SBFx5 solution: Influence of magnesium. *Biomaterials* 2002;23:2211-20.
 21. Budiatin AS, Gani MA, Samirah, Ardianto C, Raharjanti AM, Septiani I, *et al.* Bovine hydroxyapatite-based bone scaffold with gentamicin accelerates vascularization and remodeling of bone defect. *Int J Biomater* 2021;2021:5560891.

also developed by scimago:



SCIMAGO INSTITUTIONS RANKINGS

SJR

Scimago Journal & Co Enter Journal Title, ISSN or Publisher Name

[Home](#)[Journal Rankings](#)[Country Rankings](#)[Viz Tools](#)[Help](#)[About Us](#)

Journal of Advanced Pharmaceutical Technology and Research

COUNTRY[India](#)

Universities and research institutions in India

SUBJECT AREA AND CATEGORY[Pharmacology, Toxicology and Pharmaceutics](#)
[Pharmaceutical Science](#)**PUBLISHER**[Wolters Kluwer Medknow Publications](#)**H-INDEX****38****PUBLICATION TYPE**[Journals](#)**ISSN**01105558,
09762094**COVERAGE**


2010-2021

INFORMATION[Homepage](#)[How to publish in this journal](#)editor@japtr.org

SCOPE




Journal of Advanced Pharmaceutical Technology & Research (JAPTR) is an Official Publication of Society of Pharmaceutical Education & Research™. It is an international journal published Quarterly. Journal of Advanced Pharmaceutical Technology & Research (JAPTR) is available in online and print version. It is a peer reviewed journal aiming to communicate high quality original research work, reviews, short communications, case report, Ethics Forum, Education Forum and Letter to editor that contribute significantly to further the scientific knowledge related to the field of Pharmacy i.e. Pharmaceutics, Pharmacology, Pharmacognosy, Pharmaceutical Chemistry. Articles with timely interest and newer research concepts will be given more preference.

 Join the conversation about this journal

 Quartiles

**FIND SIMILAR JOURNALS** 


<p>1 Brazilian Journal of Pharmaceutical Sciences BRA</p>	<p>2 Saudi Pharmaceutical Journal SAU</p>	<p>3 DARU, Journal c Pharmaceutical GBR</p>
<p>41% similarity</p>	<p>40% similarity</p>	<p>39 simila</p>



- Cites / Doc. (4 years)
- Cites / Doc. (3 years)
- Cites / Doc. (2 years)



us® data as of April 2022




do saber cual es el factor de impacto de un



SCImago Team

for your comment.

uses Scopus data, our impact indicator is made in June 2020. We suggest you consult other indicators (like Impact Factor) with a Web ds, SCImago Team



SCImago Team

Dear Eden, thanks for your participation! Best Regards, SCImago Team



A

Journal

different in the website than those in SJR

website



← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com/journalsearch.php?q=19700201137&tip...">
```

as soon as possible.

Regards..

SCImago Graphica

Explore, visually communicate and make sense of new data tool.



Melanie Ortiz 3 years ago

SCImago Team

Dear Amina,

SJR is a portal with scientometric indicators of journals indexed in Scopus. SJR has no authority over the data of the journals; they are the ones that Scopus sends us. The metadata are property of Scopus. SCImago has a signed agreement that limits our performance to the generation of scientometric indicators derived from the metadata sent in the last update. We suggest that you contact Scopus through this link to report the inconsistencies or modifications that you want to make in SCImago:

https://service.elsevier.com/app/answers/detail/a_id/14883/kw/scimago/supporthub/scopus/. Best Regards, SCImago Team

A **Amina** 3 years ago

Hi

Can you send me the website of this journal as soon as possible plz.

Regards

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Amina, you can see the updated information just above. Best Regards,
SCImago Team

M Mohamed 3 years ago

<http://www.japtr.org/>



Melanie Ortiz 3 years ago

SCImago Team

Dear Mohamed, thanks for your participation! Best Regards, SCImago
Team

Leave a comment

Name

Email

(will not be published)

[Submit](#)

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS

Horatio (Satire 1,1,106)

[Edit Cookie Consent](#)